Your shopping cart is currently empty

CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | - | In Stock | |
| 2 mg | $44 | - | In Stock | |
| 5 mg | $72 | - | In Stock | |
| 10 mg | $113 | - | In Stock | |
| 25 mg | $239 | - | In Stock | |
| 50 mg | $347 | - | In Stock | |
| 100 mg | $537 | - | In Stock | |
| 200 mg | $759 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $79 | - | In Stock |
| Description | CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs). |
| In vitro | CCR6 antagonist 1 (50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1]. |
| In vivo | CCR6 antagonist 1 (1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1]. |
| Molecular Weight | 319.28 |
| Formula | C17H12F3NO2 |
| Cas No. | 588674-64-0 |
| Smiles | Cc1c(oc2ccccc12)C(=O)Nc1ccc(cc1)C(F)(F)F |
| Relative Density. | 1.358 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (281.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1 mg/mL (3.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.